Your browser doesn't support javascript.
loading
SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up.
Moncunill, Gemma; Mayor, Alfredo; Santano, Rebeca; Jiménez, Alfons; Vidal, Marta; Tortajada, Marta; Sanz, Sergi; Méndez, Susana; Llupià, Anna; Aguilar, Ruth; Alonso, Selena; Barrios, Diana; Carolis, Carlo; Cisteró, Pau; Chóliz, Eugenia; Cruz, Angeline; Fochs, Silvia; Jairoce, Chenjerai; Hecht, Jochen; Lamoglia, Montserrat; Martínez, Mikel J; Moreno, Javier; Mitchell, Robert A; Ortega, Natalia; Pey, Nuria; Puyol, Laura; Ribes, Marta; Rosell, Neus; Figueroa-Romero, Antía; Sotomayor, Patricia; Torres, Sara; Williams, Sarah; Barroso, Sonia; Vilella, Anna; Trilla, Antoni; Varela, Pilar; Dobaño, Carlota; Garcia-Basteiro, Alberto L.
Affiliation
  • Moncunill G; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Mayor A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Santano R; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Jiménez A; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
  • Vidal M; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Tortajada M; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Sanz S; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Méndez S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Llupià A; Occupational Health Department, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Aguilar R; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Alonso S; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Barrios D; Department of Basic Clinical Practice, Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain.
  • Carolis C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Cisteró P; Spanish Consortium for Research in Epidemiology and Public Health, Madrid, Spain.
  • Chóliz E; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Cruz A; Department of Preventive Medicine and Epidemiology, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.
  • Fochs S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Jairoce C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Hecht J; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Lamoglia M; Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Martínez MJ; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Moreno J; Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain.
  • Mitchell RA; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Ortega N; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Pey N; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Puyol L; Centro de Investigação em Saúde de Manhiça, Maputo, Mozambique.
  • Ribes M; Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
  • Rosell N; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Figueroa-Romero A; Faculty of Health Sciences of Blanquerna, Universitat Ramon Llull de Barcelona, Barcelona, Spain.
  • Sotomayor P; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Torres S; Department of Microbiology, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain.
  • Williams S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Barroso S; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Vilella A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Trilla A; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Varela P; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Dobaño C; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
  • Garcia-Basteiro AL; ISGlobal, Hospital Clínic, Universitat de Barcelona, Barcelona, Catalonia, Spain.
J Infect Dis ; 223(1): 62-71, 2021 01 04.
Article in En | MEDLINE | ID: mdl-33175145
BACKGROUND: At the COVID-19 spring 2020 pandemic peak in Spain, prevalence of SARS-CoV-2 infection in a cohort of 578 randomly selected health care workers (HCWs) from Hospital Clínic de Barcelona was 11.2%. METHODS: A follow-up survey 1 month later (April-May 2020) measured infection by rRT-PCR and IgM, IgA, and IgG to the receptor-binding domain of the spike protein by Luminex. Antibody kinetics, including IgG subclasses, was assessed until month 3. RESULTS: At month 1, the prevalence of infection measured by rRT-PCR and serology was 14.9% (84/565) and seroprevalence 14.5% (82/565). We found 25 (5%) new infections in 501 participants without previous evidence of infection. IgM, IgG, and IgA levels declined in 3 months (antibody decay rates 0.15 [95% CI, .11-.19], 0.66 [95% CI, .54-.82], and 0.12 [95% CI, .09-.16], respectively), and 68.33% of HCWs had seroreverted for IgM, 3.08% for IgG, and 24.29% for IgA. The most frequent subclass responses were IgG1 (highest levels) and IgG2, followed by IgG3, and only IgA1 but no IgA2 was detected. CONCLUSIONS: Continuous and improved surveillance of SARS-CoV-2 infections in HCWs remains critical, particularly in high-risk groups. The observed fast decay of IgA and IgM levels has implications for seroprevalence studies using these isotypes.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Health Personnel / COVID-19 / Antibodies, Viral Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2021 Type: Article

Full text: 1 Database: MEDLINE Main subject: Health Personnel / COVID-19 / Antibodies, Viral Type of study: Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Female / Humans / Male / Middle aged Country/Region as subject: Europa Language: En Year: 2021 Type: Article